<DOC>
	<DOCNO>NCT00986557</DOCNO>
	<brief_summary>RATIONALE : An infusion cytomegalovirus-specific T lymphocyte may prevent reduce cytomegalovirus infection first year donor stem cell transplant . PURPOSE : This randomized phase II trial study T-lymphocyte infusion see well work compare standard therapy treat patient risk cytomegalovirus infection donor stem cell transplant .</brief_summary>
	<brief_title>T-Lymphocyte Infusion Standard Therapy Treating Patients Risk Cytomegalovirus Infection After Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine frequency cytomegalovirus ( CMV ) reactivation first year allogeneic stem cell transplantation ( ASCT ) patient risk CMV infection treat adoptive transfer select CMV-specific cytotoxic T-lymphocytes . Secondary - To monitor CMV-specific immune reconstitution within first year follow ASCT patient . - To determine time CMV reactivation patient . - To evaluate use antiviral therapy patient . - To determine incidence secondary CMV reactivation CMV disease patient treat regimen . - To determine incidence acute chronic graft-versus-host disease . OUTLINE : This multicenter study . After undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) use alemtuzumab-based conditioning regimen also include radiotherapy , patient randomize 1 2 treatment arm . - Arm I : Patients receive cytomegalovirus ( CMV ) -specific cytotoxic T-lymphocyte infusion day 21-90 allogeneic PBSCT . - Arm II : Patients undergo standard follow-up care receive standard antiviral therapy comprise ganciclovir IV foscarnet sodium upon detection confirmation CMV reactivation . Blood sample collect assess CMV viral load quantitative PCR . After completion study therapy , patient follow week 100 day month 1 year . PROJECTED ACCRUAL : A total 18 patient sibling donor 21 patient unrelated donor accrue arm , result total 78 patient accrue study .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Planning allogeneic peripheral blood stem cell transplantation ( PBSCT ) use condition regimen contain alemtuzumab radiotherapy Sibling match unrelated donor available Patients donor match ≥ one follow HLA allele : HLAA*0101 HLA*0201 HLAA*1101 HLAA*2402 HLAB*0702 HLAB*0801 HLAB*3502 No donor whose stem cell already collect cryopreserved prior transplant Patient donor must CMV seropositive Stem cell harvest ≥ 4.0 x 10^6 CD34 cells/kg PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior bone marrow transplantation No concurrent participation another therapeutic transplantation study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>